Cullinan Therapeutics, Inc. CGEM Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $75.08M-2.1% | $88.33M+6.4% | $103.34M+1.2% | $72.82M-36.7% | $76.66M+3.3% | ||
| $276.8M+21.8% | $289.56M-8.4% | $229.26M-51.8% | $192.66M-64.8% | $227.17M-36.7% | ||
| $9.52M-31.7% | $8.86M-43.5% | $9.64M-31.0% | $10.43M-31.9% | $13.95M+9.7% | ||
| $361.41M+13.7% | $386.76M-6.7% | $342.24M-42.2% | $275.91M-59.3% | $317.77M-28.7% | ||
| $342K-43.7% | $421K-38.4% | $489K-35.7% | $569K-31.9% | $607K-33.5% | ||
| $2.44M+57.2% | $2.63M+57.8% | $1.05M-48.2% | $1.18M-44.4% | $1.55M-33.6% | ||
| $297K-18.9% | $297K-18.9% | $361K-21.5% | $367K-20.2% | $366K-20.4% | ||
| $38.5M-85.2% | $58.27M-71.5% | $140M+141% | $242.3M— | $259.39M— | ||
| $402.98M-30.5% | $448.37M-27.9% | $484.13M-25.9% | $520.33M-23.6% | $579.68M+29.0% | ||
| $2.51M-26.2% | $841K-50.0% | $1.72M-18.6% | $2.46M+58.3% | $3.4M-8.3% | ||
| $31.92M+41.2% | $36.12M+30.6% | $29.85M+43.3% | $24.2M+16.9% | $22.6M+33.8% | ||
| $725K-46.2% | $780K-40.1% | $1.19M-5.6% | $1.39M+14.7% | $1.35M+1.4% | ||
| $35.15M+28.5% | $37.74M+23.1% | $32.76M+35.3% | $28.06M+19.5% | $27.35M+24.7% | ||
| $1.66M+236% | $1.9M+124% | $0-100% | $125K-91.8% | $493K-73.2% | ||
| $2.38M+29.5% | $2.68M+24.7% | $1.19M-51.4% | $1.52M-44.4% | $1.84M-41.9% | ||
| $36.81M+32.2% | $39.64M+25.9% | $32.76M+29.0% | $28.18M+12.8% | $27.84M+17.2% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K+50.0% | ||
| $1B+3.7% | $995.82M+3.9% | $987.8M+4.3% | $978.33M+4.4% | $968.07M+45.8% | ||
| -$637.78M-53.0% | -$588.12M-59.7% | -$537.41M-67.6% | -$486.8M-73.8% | -$416.74M-75.1% | ||
| $127K-74.9% | $1.02M+867% | $973K+0.3% | $607K+228% | $505K+253% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $408.73M-30.8% | $451.37M-28.1% | $492.15M-25.0% | $551.84M+29.6% | ||
| $402.98M-30.5% | $448.37M-27.9% | $484.13M-25.9% | $520.33M-23.6% | $579.68M+29.0% | ||
| $297K-18.9% | $297K-18.9% | $361K-21.5% | $367K-20.2% | $366K-20.4% | ||
| $2.44M+57.2% | $2.63M+57.8% | $1.05M-48.2% | $1.18M-44.4% | $1.55M-33.6% | ||
| $38.5M-85.2% | $58.27M-71.5% | $140M+141% | $242.3M— | $259.39M— | ||
| $2.44M+57.2% | $2.63M+57.8% | $1.05M-48.2% | $1.18M-44.4% | $1.55M-33.6% | ||
| $297K-18.9% | $297K-18.9% | $361K-21.5% | $367K-20.2% | $366K-20.4% | ||
| $276.8M+21.8% | $289.56M-8.4% | $229.26M-51.8% | $192.66M-64.8% | $227.17M-36.7% | ||
| $2.44M+57.2% | $2.63M+57.8% | $1.05M-48.2% | $1.18M-44.4% | $1.55M-33.6% | ||
| $297K-18.9% | $297K-18.9% | $361K-21.5% | $367K-20.2% | $366K-20.4% | ||
| $31.92M+41.2% | $36.12M+30.6% | $29.85M+43.3% | $24.2M+16.9% | $22.6M+33.8% | ||
| $31.92M+41.2% | $36.12M+30.6% | $29.85M+43.3% | $24.2M+16.9% | $22.6M+33.8% | ||
| $2.38M+29.5% | $2.68M+24.7% | $1.19M-51.4% | $1.52M-44.4% | $1.84M-41.9% | ||
| $1B+3.7% | $995.82M+3.9% | $987.8M+4.3% | $978.33M+4.4% | $968.07M+45.8% | ||
| $6K0.0% | $6K0.0% | $6K0.0% | $6K0.0% | $6K+50.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9.52M-31.7% | $8.86M-43.5% | $9.64M-31.0% | $10.43M-31.9% | $13.95M+9.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cullinan Therapeutics, Inc.'s total assets?
- Cullinan Therapeutics, Inc. (CGEM) holds $403.0M in total assets, down 30.5% year over year.
- How much cash does Cullinan Therapeutics, Inc. have?
- Cullinan Therapeutics, Inc. holds $75.1M in cash and equivalents.
- Can Cullinan Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 10.28 — current assets exceed current liabilities.
- Where does Cullinan Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Cullinan Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.